Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-07 02:02 UTC

BIOMED PULSE

July 7, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 1,460 confirmed cases and 452 deaths as of July 1, marking a rapid and deadly escalation that remains the dominant global health emergency of 2026. [1]

Mood: Cautiously grim on outbreak containment; guardedly hopeful as the first-ever treatment trial for Bundibugyo virus disease opened enrollment on July 2. [2]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS - DRC AND UGANDA (PHEIC)

  • As of July 1, 2026, DRC has reported 1,460 confirmed cases and 452 confirmed deaths from Bundibugyo virus disease (BVD), the outbreak having spread rapidly from Ituri Province since first confirmed on May 14. [1]
  • Uganda continues to report cross-border BVD transmission, with the outbreak declared a Public Health Emergency of International Concern by WHO Director-General Tedros on May 17, 2026. [3][4][5]
  • WHO's IHR Emergency Committee determined the event does not yet meet criteria for a pandemic emergency but issued temporary recommendations for international travel and border measures. [6]
  • Africa CDC and WHO launched a joint continental Ebola response plan on June 5 targeting US $518 million in funding to support African country preparedness and response. [7]
  • WHO released its first-ever comprehensive clinical management guidelines for filovirus disease, covering all Ebola and Marburg virus types, on June 17 to aid frontline clinicians. [8]
  • WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing on July 2, enabling rapid genetic detection from blood samples at outbreak sites. [9]
  • The PARTNERS clinical trial opened patient enrollment in DRC on July 2, representing the first scientific effort to identify effective treatments specifically for Bundibugyo virus disease. [2]
  • Enhanced Ebola airport screening, initially begun at Washington Dulles International Airport on May 21, expanded to Atlanta Hartsfield-Jackson on May 23. [10]

HANTAVIRUS - ANDES VIRUS, M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • The fifth WHO Disease Outbreak News report on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius was published July 2, with the outbreak tracing to severe acute respiratory illness cases first reported aboard the vessel on May 2, 2026.
  • Initial notification documented 7 cases (2 laboratory confirmed, 5 suspected) among 147 passengers and crew; subsequent updates confirmed additional cases and multi-country spread as passengers disembarked across 23 nations.
  • WHO Director-General sent a follow-up message to the people of Tenerife on May 14 thanking them for cooperation in the safe disembarkation and care of over 120 passengers during the response.
  • CDC's June 24, 2026 transcript confirms ongoing US government hantavirus response monitoring with public risk described as extremely low.

NIPAH VIRUS - INDIA AND BANGLADESH

  • A laboratory-confirmed Nipah virus (NiV) case was reported from Kozhikode district, Kerala, India on June 11, 2026, involving an adult male with neurological symptoms, hospitalized June 10.
  • Earlier in 2026, India notified WHO on January 30 of two healthcare worker NiV cases at a private hospital in Barasat, North 24 Parganas, West Bengal.
  • Bangladesh reported one confirmed NiV case in Rajshahi Division on February 6, 2026, with fever and neurological onset January 21.

WEST NILE VIRUS - UNITED STATES

  • CDC issued a July 1, 2026 public advisory noting an early West Nile season with record case counts, urging Americans to take mosquito-bite prevention measures during the July 4th Independence Day holiday weekend.

MPOX - RECOMBINANT STRAIN

  • WHO documented two cases of a novel recombinant mpox strain containing genomic elements of both clade Ib and clade IIb monkeypox virus (MPXV), a naturally occurring process when two related viruses co-infect the same individual, reported globally as of February 14, 2026.

YELLOW FEVER - GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections with deaths, following elevated activity in the Americas that began in 2025 and continued into 2026, according to WHO.

MEASLES - BANGLADESH AND UNITED STATES

  • Bangladesh notified WHO on April 4, 2026 of a nationwide measles surge affecting 58 of 64 districts, with 19,161 suspected cases and 2,897 laboratory-confirmed cases across all 8 divisions.
  • CDC reaffirmed national measles response collaboration with state health departments as of March 9, 2026, following a Texas outbreak that included two confirmed measles deaths in early 2025.

AVIAN INFLUENZA A(H9N2) - ITALY

  • Italy notified WHO on March 21, 2026 of one human A(H9N2) case in an adult male returning from Senegal, confirmed by next-generation sequencing.

SALMONELLA - MULTIPLE ACTIVE US OUTBREAKS

  • A Salmonella outbreak linked to backyard poultry, updated May 14, 2026, had sickened 150 additional people, with over one quarter of cases in children under 5.
  • CDC issued a separate alert on April 23, 2026 for a new Salmonella outbreak in 13 states linked to backyard poultry affecting 34 people.
  • A growing multi-outbreak alert tied to moringa leaf products was updated May 27, 2026, with extensively drug-resistant Salmonella from moringa powder capsules first flagged February 13, 2026.

LISTERIA - REQUESÓN/SOFT RICOTTA CHEESE AND PREPARED MEALS

  • CDC warned June 5, 2026 of a Listeria outbreak linked to requesón and soft ricotta cheese.
  • A separate Listeria outbreak tied to prepared meals continued through at least October-November 2025, expanded to additional products, with ongoing illnesses reported despite recalls.

INFANT BOTULISM - NARA ORGANICS FORMULA

  • CDC outbreak update on June 13, 2026 urged parents to immediately stop using all Nara Organics Whole Milk Organic Infant Formula, linked to an infant botulism investigation.

NEW WORLD SCREWWORM

  • CDC activated its Emergency Operations Center on June 12, 2026 to coordinate a response to New World screwworm (Cochliomyia hominivorax), a parasitic fly larvae infestation that poses risk to humans and animals.

TICK BITES - SEASONAL SURGE

  • CDC data released April 23, 2026 showed weekly emergency room visits for tick bites are higher than usual for this point in the season, prompting public advisories.

DRUG-RESISTANT BACTERIA

  • A CDC report released September 23, 2025 documented a dramatic rise in dangerous drug-resistant bacteria in the United States, underscoring antimicrobial resistance as an accelerating public health threat.

🧬 LONGEVITY & AGING

DELIRIUM AS POTENTIAL BRIDGE FROM INFECTION TO DEMENTIA

  • Two commentaries in Lancet Healthy Longevity (Sipilä/Kivimäki and Penfold/Jiwaji/MacLullich) propose delirium — acute brain dysfunction triggered by severe infection — as a mechanistic missing link explaining why serious infections can accelerate subsequent dementia risk.
  • The hypothesis is clinically significant given the ongoing Ebola and hantavirus outbreaks, as survivors of neurotropic infections may face elevated long-term cognitive risk.

UROLITHIN A AND AGING PANCREAS - CLINICAL TRIAL

  • A randomized triple-masked trial (NCT06274749) is evaluating whether urolithin A (UA), a natural gut-derived compound, can improve glucose metabolism in adults aged 55 and older, targeting the age-related decline of pancreatic insulin-secreting cells.

NAD+ HOMEOSTASIS AND BONE REPAIR IN AGING

  • A Europe PMC study published June 27, 2026 reports a novel hierarchical scaffold that modulates senescent metabolism, restoring NAD+ homeostasis and redox balance in aged bone tissue, potentially enabling repair in elderly patients whose bones heal poorly due to cellular aging.

INSULIN RESISTANCE AND MILD COGNITIVE IMPAIRMENT

  • A study in Scandinavian Journal of Primary Health Care (Rotonen et al., June 23, 2026) found associations between insulin resistance, reduced health-related quality of life, and mild cognitive impairment during aging, adding metabolic health to the cognitive decline risk picture.

NINE-GENE SENESCENCE MODULE IN CARTILAGE CELLS

  • Researchers publishing in Regenerative Therapy (Alemujiang et al., June 13, 2026) identified a conserved nine-gene decline module in long-term expanded auricular chondrocytes that drives dedifferentiation independently of classical cellular senescence, with implications for cartilage and tissue-regeneration therapies.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • A Toxicology Reports study (Iorjiim et al., June 25, 2026) found kaempferol extracted from Moringa oleifera increases longevity and reduces efavirenz-induced functional senescence in Drosophila melanogaster, providing early mechanistic data for this plant compound's anti-aging potential.

CHRONIC KIDNEY DISEASE AND MULTIMORBIDITY MORTALITY

  • The NURTuRE-CKD multicentre cohort study published in Annals of Medicine (June 23, 2026) found that multiple coexisting long-term conditions significantly worsen mortality, kidney failure progression, and quality of life among people with chronic kidney disease.

PHYSICAL ACTIVITY RESTRICTION AND DEMENTIA RISK IN JAPAN

  • An ecological panel study across 47 Japanese prefectures (2013-2022) published in Dialogues in Health (Kimura, June 2026) linked structural physical activity restrictions to higher cerebrovascular and diabetes mortality and increased long-term care intensity, with a COVID-19 counterfactual analysis.

TOBACCO BURDEN ON METABOLIC LIVER DISEASE

  • A global burden study in Journal of Diabetes and Metabolic Disorders (Xu et al., July 3, 2026) quantified tobacco's contribution to metabolic dysfunction-associated steatotic liver disease (MASLD) from 1990 to 2023 and projected continued rise through 2038.

ALZHEIMER'S DISEASE - MK-2214 PHASE 2 TRIAL

  • A Phase 2 trial (NCT07033494, MK-2214-004) is actively enrolling adults with early Alzheimer's disease to assess whether MK-2214 can slow pathological brain changes associated with the disease's progression.

SLEEP AND ALZHEIMER'S RISK

  • Trial NCT05138848 is evaluating time-in-bed restriction as a behavioral intervention for sleep difficulties in older adults at risk for Alzheimer's disease, grounded in evidence that sleep is a modifiable factor in neurodegeneration; Alzheimer's affects approximately 5.6 million US adults over 65.

CARE FOR AMERICA'S AGING - DEMENTIA CAREGIVER TRIAL

  • A randomized pilot study (NCT06021704) is testing whether enhanced dementia-specific curriculum training for home health aides improves behavioral symptoms in persons living with dementia or cognitive impairment (PLWD/CI).

INFLUENZA VACCINATION IN ELDERLY - VIETNAM TRIAL

  • A cluster-randomised controlled trial (NCT07508189) in Can Tho City, Vietnam is evaluating a multi-component community communication intervention to increase influenza vaccination rates in adults over 65.

💊 NEW CURES & APPROVALS

  • LUMVOA (veligrotug-vvze), sponsor Viridian Therapeutics Inc, received an original FDA approval (ORIG AP, BLA761530); veligrotug is a novel biologic targeting thyroid eye disease via the IGF-1R pathway.
  • SKYRIZI (risankizumab-rzaa), sponsor AbbVie Inc, received supplemental approvals on two biologics license applications (BLA761262 and BLA761105), indicating new indications or formulations for this IL-23 inhibitor used in plaque psoriasis, psoriatic arthritis, and inflammatory bowel disease.
  • ROMVIMZA (vimseltinib), sponsor Deciphera Pharmaceuticals, received a supplemental approval (NDA219304); vimseltinib is a CSF1R kinase inhibitor for tenosynovial giant cell tumor.
  • SARCLISA (isatuximab-irfc), sponsor Sanofi Aventis US, received a supplemental approval (BLA761113) for this CD38-targeting monoclonal antibody used in multiple myeloma.
  • BESREMI (ropeginterferon alfa-2b-njft), sponsor PharmaEssentia Corp, received a supplemental approval (BLA761166) for this long-acting interferon used in polycythemia vera.
  • ZEVTERA (ceftobiprole medocaril sodium), sponsor ISTX, received a supplemental approval (NDA218275); ceftobiprole is a broad-spectrum cephalosporin antibiotic active against MRSA.
  • RINVOQ LQ (upadacitinib), sponsor AbbVie, received a supplemental approval (NDA218347) for a liquid formulation of this JAK1 inhibitor, expanding access for patients who cannot swallow tablets.
  • TRELSTAR (triptorelin pamoate), sponsor Verity, received supplemental approvals on three NDAs (020715, 022437, 021288); triptorelin is a GnRH agonist used in advanced prostate cancer and precocious puberty.

🧪 CLINICAL TRIALS

UROLITHIN A - GLUCOSE METABOLISM IN ADULTS 55 PLUS (NCT06274749)

  • Randomized triple-masked controlled trial testing urolithin A supplementation on insulin secretion and blood glucose in healthy adults aged 55 and older, targeting aging-related pancreatic decline.

MK-2214 FOR EARLY ALZHEIMER'S DISEASE (NCT07033494)

  • Phase 2 study enrolling adults with early AD to evaluate whether MK-2214 slows characteristic brain changes; Merck-sponsored trial tracking cognitive and biomarker endpoints.

PACRITINIB FOR MYELODYSPLASTIC SYNDROMES (NCT06303193)

  • Trial of pacritinib, a multi-kinase inhibitor targeting CSF1R, IRAK1, JAK2, and FLT3, in adults and pediatric patients age 12 and older with MDS or MDS/MPN, conditions that can progress to acute myeloid leukemia.

SLEEP RESTRICTION AND ALZHEIMER'S RISK IN OLDER ADULTS (NCT05138848)

  • Evaluating time-in-bed restriction behavioral therapy for sleep difficulties in older adults with and without Alzheimer's disease risk factors; projected AD costs expected to rise from $307 billion to $1.5 trillion over 30 years.

CARE FOR AMERICA'S AGING STUDY (NCT06021704)

  • Randomized pilot study testing dementia-specific home health aide training to reduce behavioral symptoms of dementia and improve global outcomes in persons living with dementia or cognitive impairment.

177LU-DOTA-EB-TATE FOR ONCOCYTIC THYROID CANCER (NCT06991738)

  • Testing a radioactive compound that targets a protein overexpressed on Hurthle cell thyroid cancer cells, a rare cancer with few existing treatment options.

DOCETAXEL PLUS SX-682 IN HEAD AND NECK AND PROSTATE CANCERS (NCT07667400)

  • Combination trial in recurrent or metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer; prostate cancer is the most common cancer in US men with survival below 50% once metastatic.

EHR NUDGES FOR BREAST CANCER SCREENING (NCT06177795)

  • Evaluating personalized electronic health record nudges to clinicians and patients to improve breast cancer screening rates in accordance with USPSTF guidelines, with emphasis on high-risk women.

LMP744 FOR RECURRENT GLIOBLASTOMA (NCT07416188)

  • Testing LMP744, a novel indenoisoquinolone c-MYC and topoisomerase 1 inhibitor, in adults with glioblastoma that has returned after standard surgery, radiation, and chemotherapy.

INFLUENZA VACCINATION COMMUNICATION INTERVENTION IN ELDERLY - VIETNAM (NCT07508189)

  • Cluster-randomised trial in Can Tho City testing a multi-component community-based communication strategy to raise influenza vaccination uptake in adults over age 65.

BREATHWORK AFTER KNEE SURGERY IN OLDER ADULTS (NCT07464860)

  • Feasibility trial assessing breathwork interventions for postoperative complications after total knee arthroplasty in adults aged 65 and older, who are particularly vulnerable to post-surgical morbidity.

📢 PUBLIC HEALTH

WHO FOOD SAFETY ESTIMATES 2026

  • WHO released new estimates on June 4, 2026 showing unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide, with children under five facing nearly three times the illness risk of older individuals.

PNEUMOCOCCAL VACCINE AGE LOWERED TO 50 IN US

  • CDC Director Mandy Cohen endorsed ACIP's recommendation on October 23, 2024 to lower the recommended age for pneumococcal vaccination from 65 to 50, expanding protection against pneumonia to a younger age group.

CDC IMMUNIZATION SCHEDULE REVISED 2025

  • CDC updated its adult and child immunization schedules in October 2025 to apply individual-based decision-making for COVID-19 vaccines and moved chickenpox vaccination in toddlers to a standalone schedule.

HEPATITIS B VACCINE - INDIVIDUAL-BASED DECISION FOR INFANTS

  • CDC adopted individual-based decision-making for hepatitis B immunization for infants born to mothers who test negative for hepatitis B virus as of December 16, 2025, following an ACIP vote.

US WITHDRAWAL FROM WHO COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 failures and politicization, with the administration announcing a shift toward bilateral health efforts.

NEW WORLD SCREWWORM EMERGENCY OPERATIONS

  • CDC activated its Emergency Operations Center on June 12, 2026 to coordinate response to New World screwworm, a parasitic fly that lays eggs in wounds of warm-blooded animals and occasionally humans.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE HITS 1 MILLION PARTICIPANTS

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants on January 30, 2026, enhancing the nation's capacity to detect novel pathogens imported via international travel.

ADVERSE OUTCOMES FROM MEDICAL TOURISM

  • CDC highlighted on June 2, 2026 a pattern of serious adverse outcomes linked to travel-related cosmetic procedures performed abroad, urging Americans to carefully evaluate risks before pursuing medical tourism.

CDC DRUG OVERDOSE DEATHS DOWN 27 PERCENT

  • Provisional 2024 data from CDC's National Vital Statistics System show a 27% decrease in drug overdose deaths in the United States, following a nearly 24% decline reported in 2023.

SYPHILIS IN NEWBORNS RISES FOR 12TH CONSECUTIVE YEAR

  • New CDC data released September 24, 2025 showed US cases of congenital syphilis increased for the 12th straight year in 2024, marking a persistent failure to control maternal-to-infant transmission.

UNSAFE INFANT FORMULA RECALL - CEREULIDE TOXIN

  • WHO Disease Outbreak News from March 13, 2026 documented multi-country recalls of infant formula and products containing arachidonic acid (ARA) oil contaminated with cereulide toxin, a heat-stable toxin produced by Bacillus cereus.

BIOMED PULSE is an informational briefing only. Nothing here constitutes medical advice. Consult qualified healthcare professionals for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Patient enrolment begins in a scientific trial to identify the… — WHO News
  3. Epidemic of Ebola Disease caused by Bundibugyo virus in the De… — WHO News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  6. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  7. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  8. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  9. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  10. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260707-02-v20 · 2026-07-07 02:02 UTC · pulse.uzylab.com

Read next